Celcuity
Kathy DeCaro, RN, BSN, currently serves as the Executive Director of Drug Safety & Pharmacovigilance at Celcuity since August 2022. With extensive experience in pharmacovigilance, Kathy has held key positions such as Sr. Director of Pharmacovigilance at MEI Pharma and Sr. Director of Global Drug Safety Operations at La Jolla Pharmaceutical Company. Kathy's previous roles include consulting in drug safety and various leadership positions in safety operations and surveillance at organizations like Agility Clinical, Mast Therapeutics, and Synteract. An expert in global regulatory requirements and clinical trial safety reporting, Kathy's education includes a Bachelor of Science in Nursing from Gwynedd Mercy University.
This person is not in any offices
Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages the CELsignia CDx platform.